Show simple item record

dc.contributor.authorBracale, Umberto Marcello
dc.contributor.authorDi Filippo, Mathilde
dc.contributor.authorDe Capua, Antonio
dc.contributor.authorVanni, Linda
dc.contributor.authorNarese, Donatella
dc.contributor.authorPecoraro, Felice
dc.contributor.authorGiribono, Anna Maria
dc.contributor.authorBracale, Renata
dc.date.accessioned2020-06-08T09:23:51Z
dc.date.available2020-06-08T09:23:51Z
dc.date.issued2018
dc.identifier.citationBracale UM, Di Filippo M, De Capua A, Vanni L, Narese D, Pecoraro F, Giribono AM, Bracale R. Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients. Translational Medicine @ UniSa 2018, 18(2): 3-8.it_IT
dc.identifier.issn2239-9747
dc.identifier.urihttp://www.translationalmedicine.unisa.it/indexit_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/4517
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2712
dc.description.abstractAngioplasty with drug-coated balloon (DCB) is an emerging and reliable method for the treatment of femoro-popliteal lesions. We report our experience with the Stellarex™ DCB in the first 50 patients. Methods - From July 2015 to November 2017, 50 patients (41 M, 9F), medium age (64 ± 7.4 year) were subject to 33 angioplasties (PTAs) for femoro-popliteal lesions with a paclitaxel-coated balloon (Stellarex™). Based upon clinical data sixteen patients had severe claudication (56% - Rutherford class 3); ten patients suffered from ischemic rest pain (34% - Rutherford class 4); and five presented minor tissue loss (10% - Rutherford class 5). 42% of patients showed femoro-popliteal lesion TASC-II B, and 58% presented lesions pertaining to TASC-II C. Results - Immediate technical success was 100% without perioperative complications. Primary patency rate was 94% at twelve months. In three cases restenosis (6%) was detected within a year from procedure, and a further PTA DCB was performed with primary assisted patency rates of 100% at twelve months. Two patients underwent major lower limb amputation. Three patients died during follow-up and one patient was lost at follow-up. Conclusion - DCB angioplasty with Stellarex™ is a viable alternative to traditional endovascular procedures proving satisfactory primary patency rates at twelve months. Based on our experience, treatment with DCB is a first choice technique for non-complex de novo lesions of the femoro – popliteal tract.it_IT
dc.format.extentP. 3-8it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectDrug-coated balloonit_IT
dc.subjectPeripheral arterial diseaseit_IT
dc.subjectSuperficial femoral arteryit_IT
dc.subjectEndovascular treatmentit_IT
dc.titleTreatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patientsit_IT
dc.typeArticleit_IT
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record